Clinical trial
A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine and Ibrutinib in Patients With Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3)
NCT03684694 is registered in ClinicalTrials.gov with ADC Therapeutics S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine and Ibrutinib in Patients With Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3)
- Lead sponsor
- ADC Therapeutics S.A.
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- December 1, 2018
- Completion date
- November 8, 2022
- Enrollment
- 136 (actual)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.
diffuse large b-cell lymphoma, mantle cell lymphoma